成人减重行为与药物干预预防肥胖相关疾病:USPSTF更新证据报告与系统综述
行为干预在12-18个月平均减重-2.39 kg(95%CI -2.86至-1.93),并减少体重反弹;药物干预减重范围-0.6至-5.8 kg;糖尿病前期患者减重干预后糖尿病风险降低(RR 0.67,95%CI 0.51至0.89)。行为干预无危害证据,药物干预不良事件率更高。
要点
- 行为减重干预12-18个月平均减重2.39 kg,并减少体重反弹1.59 kg。
- 药物减重干预12-18个月减重范围0.6至5.8 kg,但不良事件率高于安慰剂。
- 糖尿病前期患者减重干预可降低糖尿病风险(RR 0.67)。
核心结论
- 行为减重干预伴或不伴药物均与更多减重和较低糖尿病风险相关。
- 减重药物而非行为干预与更高危害率相关。
- 长期体重和健康结局数据以及重要亚组数据有限。
研究设计与样本
- 检索MEDLINE、PubMed、PsycINFO、Cochrane Central等数据库至2017年6月6日。
- 对行为干预减重结局进行随机效应荟萃分析。
主要发现
- 行为干预12-18个月平均减重-2.39 kg(95%CI -2.86至-1.93;67项研究,n=22065)。
- 行为干预减少体重反弹-1.59 kg(95%CI -2.38至-0.79;8项研究,n=1408)。
- 药物干预12-18个月减重或减少反弹范围-0.6至-5.8 kg(未行荟萃分析)。
- 糖尿病前期患者减重干预后糖尿病风险RR 0.67(95%CI 0.51至0.89)。
- 行为干预无心血管疾病等危害证据;药物组不良事件率和脱落率更高。
临床怎么用
- 行为减重干预可作为成人减重和维持的首选策略,无危害证据。
- 药物减重需权衡获益与更高不良事件风险,尤其注意脱落率。
- 糖尿病前期成人可通过减重干预降低糖尿病风险。
局限性
- 长期体重和健康结局数据有限。
- 重要亚组数据有限。
- 死亡率、心血管疾病和癌症等健康结局报告不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Overweight and obesity have been associated with adverse health effects. OBJECTIVE: To systematically review evidence on benefits and harms of behavioral and pharmacotherapy weight loss and weight loss maintenance interventions in adults to inform the US Preventive Services Task Force. DATA SOURCES: MEDLINE, PubMed Publisher-Supplied Records, PsycINFO, and the Cochrane Central Register of Controlled Trials for studies published through June 6, 2017; ClinicalTrials.gov and the World Health Organization International Clinical Trials Registry Platform for ongoing trials through August 2017; and ongoing surveillance in targeted publications through March 23, 2018. Studies from previous reviews were reevaluated for inclusion. STUDY SELECTION: Randomized clinical trials (RCTs) focusing on weight loss or weight loss maintenance in adults. DATA EXTRACTION AND SYNTHESIS: Data were abstracted by one reviewer and confirmed by another. Random-effects meta-analyses were conducted for weight loss outcomes in behavior-based interventions. MAIN OUTCOMES AND MEASURES: Health outcomes, weight loss or weight loss maintenance, reduction in obesity-related conditions, and adverse events. RESULTS: A total of 122 RCTs (N = 62 533) and 2 observational studies (N = 209 993) were identified. Compared with controls, participants in behavior-based interventions had greater mean weight loss at 12 to 18 months (-2.39 kg [95% CI, -2.86 to -1.93]; 67 studies [n = 22065]) and less weight regain (-1.59 kg [95% CI, -2.38 to -0.79]; 8 studies [n = 1408]). Studies of medication-based weight loss and maintenance interventions also reported greater weight loss or less weight regain in intervention compared with placebo groups at 12 to 18 months (range, -0.6 to -5.8 kg; no meta-analysis). Participants with prediabetes in weight loss interventions had a lower risk of developing diabetes compared with controls (relative risk, 0.67 [95% CI, 0.51 to 0.89]). There was no evidence of other benefits, but most health outcomes such as mortality, cardiovascular disease, and cancer were infrequently reported. Small improvements in quality of life in some medication trials were noted but were of unclear clinical significance. There was no evidence of harm such as cardiovascular disease from behavior-based interventions; higher rates of adverse events were associated with higher dropout rates in medication groups than in placebo groups. CONCLUSIONS AND RELEVANCE: Behavior-based weight loss interventions with or without weight loss medications were associated with more weight loss and a lower risk of developing diabetes than control conditions. Weight loss medications, but not behavior-based interventions, were associated with higher rates of harms. Long-term weight and health outcomes data, as well as data on important subgroups, were limited.
引用
- LeBlanc ES, Patnode CD, Webber EM, et al. Behavioral and Pharmacotherapy Weight Loss Interventions to Prevent Obesity-Related Morbidity and Mortality in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2018. PMID: 30326501. doi:10.1001/jama.2018.7777
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。